ISTH interim guidance on recognition and management of coagulopathy in COVID-19

doi:10.1111/jth.14810

Practice Guideline

. 2020 May;18(5):1023-1026.

doi: 10.1111/jth.14810. Epub 2020 Apr 27.

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Jecko Thachil¹, Ning Tang², Satoshi Gando³, Anna Falanga^{4

5}, Marco Cattaneo⁶, Marcel Levi⁷, Cary Clark⁸, Toshiaki Iba⁹

Affiliations

¹ Department of Haematology, Manchester University Hospitals, Manchester, UK.
² Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
³ Department of Acute and Critical Care Medicine, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan.
⁴ Department of Transfusion Medicine and Hematology, Hospital Papa Giovanni XXIII, Bergamo, Italy.
⁵ University of Milan Bicocca, Monza, Italy.
⁶ Dipartimento di Scienze della Salute, Università degli Studi di Milano, ASST Santi Paolo e Carlo, Milan, Italy.
⁷ Department of Medicine and Cardio-metabolic Programme-NIHR UCLH/UCL BRC, University College London Hospitals NHS Foundation Trust, London, UK.
⁸ Director of Programs and Education, International Society on Thrombosis and Haemostasis, Carrboro, North Carolina.
⁹ Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

PMID: 32338827
PMCID: PMC9906133
DOI: 10.1111/jth.14810

Practice Guideline

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Jecko Thachil et al. J Thromb Haemost. 2020 May.

. 2020 May;18(5):1023-1026.

doi: 10.1111/jth.14810. Epub 2020 Apr 27.

Authors

Jecko Thachil¹, Ning Tang², Satoshi Gando³, Anna Falanga^{4

5}, Marco Cattaneo⁶, Marcel Levi⁷, Cary Clark⁸, Toshiaki Iba⁹

Affiliations

¹ Department of Haematology, Manchester University Hospitals, Manchester, UK.
² Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
³ Department of Acute and Critical Care Medicine, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan.
⁴ Department of Transfusion Medicine and Hematology, Hospital Papa Giovanni XXIII, Bergamo, Italy.
⁵ University of Milan Bicocca, Monza, Italy.
⁶ Dipartimento di Scienze della Salute, Università degli Studi di Milano, ASST Santi Paolo e Carlo, Milan, Italy.
⁷ Department of Medicine and Cardio-metabolic Programme-NIHR UCLH/UCL BRC, University College London Hospitals NHS Foundation Trust, London, UK.
⁸ Director of Programs and Education, International Society on Thrombosis and Haemostasis, Carrboro, North Carolina.
⁹ Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

PMID: 32338827
PMCID: PMC9906133
DOI: 10.1111/jth.14810

No abstract available

PubMed Disclaimer

Figures

**Figure 1**
Algorithm for the management of coagulopathy in COVID‐19 based on simple laboratory markers. * The list of markers is given in decreasing order of importance. ** Performing fibrinogen assays may not be feasible in many laboratories but monitoring the levels can be helpful after patient admission. *** Although a specific cut‐off cannot be defined, a three‐ to four‐fold increase in D‐dimer values may be considered significant. Any one of the values in this table may be considered significant

See this image and copyright information in PMC

Comment in

RE: ISTH interim guidance to recognition and management of coagulopathy in COVID-19.
Akima S, McLintock C, Hunt BJ. Akima S, et al. J Thromb Haemost. 2020 Aug;18(8):2057-2058. doi: 10.1111/jth.14853. Epub 2020 Jul 15. J Thromb Haemost. 2020. PMID: 32302442 Free PMC article. No abstract available.
ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A comment.
Barrett CD, Moore HB, Yaffe MB, Moore EE. Barrett CD, et al. J Thromb Haemost. 2020 Aug;18(8):2060-2063. doi: 10.1111/jth.14860. Epub 2020 Jun 14. J Thromb Haemost. 2020. PMID: 32302462 Free PMC article. No abstract available.
Occurrence of pulmonary embolism in a patient with mild clinical expression of COVID-19.
Vitali C, Minniti A, Caporali R, Del Papa N. Vitali C, et al. Thromb Res. 2020 Aug;192:21-22. doi: 10.1016/j.thromres.2020.05.002. Epub 2020 May 5. Thromb Res. 2020. PMID: 32416365 Free PMC article. No abstract available.
Reduction of venous thromboembolic events in COVID-19 patients: Which role for IL-6 antagonists?
Zuin M, Cervellati C, Rigatelli G, Zuliani G, Roncon L. Zuin M, et al. Thromb Res. 2021 Dec;208:170-172. doi: 10.1016/j.thromres.2021.11.008. Epub 2021 Nov 16. Thromb Res. 2021. PMID: 34801920 Free PMC article. No abstract available.

Cited by

Treatment and long term follow-up results in patients with pulmonary vascular thrombosis related to COVID-19.
Aliyeva N, Çalişkaner Öztürk B, Kiliçkiran Avci B, Atahan E. Aliyeva N, et al. Medicine (Baltimore). 2024 Nov 1;103(44):e40319. doi: 10.1097/MD.0000000000040319. Medicine (Baltimore). 2024. PMID: 39495981 Free PMC article.
Multifaceted Heparin: Diverse Applications beyond Anticoagulant Therapy.
Sultana R, Kamihira M. Sultana R, et al. Pharmaceuticals (Basel). 2024 Oct 12;17(10):1362. doi: 10.3390/ph17101362. Pharmaceuticals (Basel). 2024. PMID: 39459002 Free PMC article. Review.
Pro-Resolving Inflammatory Effects of a Marine Oil Enriched in Specialized Pro-Resolving Mediators (SPMs) Supplement and Its Implication in Patients with Post-COVID Syndrome (PCS).
Gracia Aznar A, Moreno Egea F, Gracia Banzo R, Gutierrez R, Rizo JM, Rodriguez-Ledo P, Nerin I, Regidor PA. Gracia Aznar A, et al. Biomedicines. 2024 Sep 29;12(10):2221. doi: 10.3390/biomedicines12102221. Biomedicines. 2024. PMID: 39457534 Free PMC article.
Immunity and Coagulation in COVID-19.
Avdonin PP, Blinova MS, Serkova AA, Komleva LA, Avdonin PV. Avdonin PP, et al. Int J Mol Sci. 2024 Oct 19;25(20):11267. doi: 10.3390/ijms252011267. Int J Mol Sci. 2024. PMID: 39457048 Free PMC article. Review.
Role of Carcinoembryonic Antigen in Severity Assessment and Mortality Prediction in COVID-19 Patients.
Anjan MAH, Ahmed QMU, Masum AA, Sami CA, Matin MA, Islam MS, Chowdhury FR, Arafat SM, Rahman M, Hasan MN. Anjan MAH, et al. Cureus. 2024 Sep 22;16(9):e69894. doi: 10.7759/cureus.69894. eCollection 2024 Sep. Cureus. 2024. PMID: 39439636 Free PMC article.

See all "Cited by" articles

References

1. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. - PMC - PubMed
1. Guan W.J., Ni Z.Y., Hu Y., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed
1. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847. - PMC - PubMed
1. Zhang J., Zhou L., Yang Y., Peng W. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet. 2019 doi: 10.1016/S2213-2600(20)30071-0. - DOI - PMC - PubMed
1. Williamson D.R., Albert M., Heels‐Ansdell D., et al. Thrombocytopenia in critically ill patients receiving thromboprophylaxis. Chest. 2013;144(4):1207–1215. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information

[1] Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. - PMC - PubMed

[2] Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. - PMC - PubMed

[3] Guan W.J., Ni Z.Y., Hu Y., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed

[4] Guan W.J., Ni Z.Y., Hu Y., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed

[5] Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847. - PMC - PubMed

[6] Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847. - PMC - PubMed

[7] Zhang J., Zhou L., Yang Y., Peng W. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet. 2019 doi: 10.1016/S2213-2600(20)30071-0. - DOI - PMC - PubMed

[8] Zhang J., Zhou L., Yang Y., Peng W. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet. 2019 doi: 10.1016/S2213-2600(20)30071-0. - DOI - PMC - PubMed

[9] Williamson D.R., Albert M., Heels‐Ansdell D., et al. Thrombocytopenia in critically ill patients receiving thromboprophylaxis. Chest. 2013;144(4):1207–1215. - PubMed

[10] Williamson D.R., Albert M., Heels‐Ansdell D., et al. Thrombocytopenia in critically ill patients receiving thromboprophylaxis. Chest. 2013;144(4):1207–1215. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Affiliations

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Authors

Affiliations

Figures

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical